How were ITUS's earnings last quarter?

ITUS Co. (NASDAQ:ITUS) issued its quarterly earnings results on Friday, March, 9th. The business services provider reported ($0.11) earnings per share (EPS) for the quarter.

What other stocks do shareholders of ITUS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ITUS investors own include Synergy Pharmaceuticals (SGYP) , Galectin Therapeutics (GALT) , Progenics Pharmaceuticals (PGNX) , Catalyst Pharmaceuticals (CPRX) , Halozyme Therapeutics (HALO) , Palatin Technologies (PTN) , Advanced Micro Devices (AMD) , Coherus BioSciences (CHRS) and CME Group (CME) .

NASDAQ:ITUS

ITUS (ITUS) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free ITUS Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $4.61
▼
$4.76
50-Day Range: N/A
52-Week Range: $1.83
▼
$6.43

Volume: 69,859 shs
Average Volume: 134,373 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get ITUS alerts:

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About ITUS Stock (NASDAQ:ITUS)

Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body's immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immune-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

Click here to find out that this 8,788% cryptocurrency is.

ITUS Stock News Headlines

April 7, 2024 | msn.com

Clear skies for your Sunday

April 6, 2024 | msn.com

Cool temperatures expected for your Saturday

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

April 5, 2024 | msn.com

Hexagon acquires Virginia-based Itus Digital

April 4, 2024 | finanznachrichten.de

Hexagon rebrands Qognify, reaffirming commitment to physical security

April 4, 2024 | finance.yahoo.com

Hexagon acquires Itus Digital to expand Asset Performance Management capabilities

April 2, 2024 | msn.com

Stellenbosch cement second spot with victory over Kaizer Chiefs

March 27, 2024 | msn.com

Man arrested in Titus County sex sting operation

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 23, 2024 | nasdaq.com

May 3rd Options Now Available For Eli Lilly (LLY)

March 18, 2024 | msn.com

Some bay clouds Monday with sunny and warm afternoon

March 17, 2024 | msn.com

Sunny skies for your Sunday

March 11, 2024 | msn.com

"A kit with some surprising tricks up its sleeve": Donner Backbeat review

March 9, 2024 | msn.com

FactChecking Biden’s State of the Union

March 7, 2024 | msn.com

Seven candidates for three seats on 5th District Court of Appeals, in all-GOP affair

February 21, 2024 | msn.com

ITU's AI for Good Global Summit 2024 puts tech to the test for people and planet

February 19, 2024 | msn.com

Chapel Hill ISD announces $9.3 million bond election for May

February 13, 2024 | msn.com

US Senate Passes Ukraine Aid Bill, House Likely To Reject It

February 6, 2024 | ft.com

Letter: One way to raise quality of classroom discussions

January 26, 2024 | msn.com

Seasonably cool Thursday with sunshine

January 14, 2024 | msn.com

‘Your Tahoe needs a tune up buddy’: Man who taunted police after escaping dangerous chase busted by his own Snapchat bragging

January 13, 2024 | msn.com

'Your Tahoe needs a tune up buddy': Man who taunted police after escaping dangerous chase busted by his own Snapchat bragging

January 10, 2024 | theglobeandmail.com

Itus Mouthguardz Earns Global Acclaim for USA Patented Anti-Snore Device

January 10, 2024 | msn.com

Scattered showers for your Wednesday

January 8, 2024 | msn.com

Opinion: Maybe it’s time for me to just accept my geezerhood?

December 24, 2023 | msn.com

Chilly weather for the holidays

December 18, 2023 | msn.com

Ndieze Lagos Warn Against Indiscriminate Conferment Of Chieftaincy Titles

See More Headlines

Receive ITUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ITUS and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/09/2018
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Business Services
Industry: Patent Owners & Lessors
Sub-Industry: N/A
Current Symbol: NASDAQ:ITUS
CUSIP: N/A
CIK: 715446
Web: www.ituscorp.com
Phone: (408) 708-9808
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Amit D. Kumar
Executive Chairman, President & CEO
Michael J. Catelani
Secretary, Chief Operating & Financial Officer
Thomas Schlumpberger
Executive Vice President-Diagnostics

Key Competitors

View All Competitors

ITUS Stock Analysis - Frequently Asked Questions

How were ITUS's earnings last quarter?: ITUS Co. (NASDAQ:ITUS) issued its quarterly earnings results on Friday, March, 9th. The business services provider reported ($0.11) earnings per share (EPS) for the quarter.
What other stocks do shareholders of ITUS own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ITUS investors own include Synergy Pharmaceuticals (SGYP), Galectin Therapeutics (GALT), Progenics Pharmaceuticals (PGNX), Catalyst Pharmaceuticals (CPRX), Halozyme Therapeutics (HALO), Palatin Technologies (PTN), Advanced Micro Devices (AMD), Coherus BioSciences (CHRS) and CME Group (CME).

This page (NASDAQ:ITUS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ITUS (ITUS) Stock Price, News & Analysis

About ITUS Stock (NASDAQ:ITUS)

ITUS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ITUS Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info